NasdaqGS:RPRXPharmaceuticals
Assessing Royalty Pharma (RPRX) Valuation After Johnson & Johnson Autoimmune Co Funding Deal
Royalty Pharma (RPRX) is back in focus after announcing a US$500 million R&D co funding agreement with Johnson & Johnson to advance JNJ-4804, an investigational autoimmune therapy targeting IL-23 and TNF pathways.
See our latest analysis for Royalty Pharma.
The J&J co funding news lands on top of an already strong run, with Royalty Pharma’s 90 day share price return of 18.98% and 1 year total shareholder return of 51.96% suggesting momentum has been building.
If this kind of deal making has...